[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Rinsho Ketsueki
; 62(11): 1639-1642, 2021.
Article
in Japanese
| MEDLINE | ID: covidwho-1555777
ABSTRACT
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic until today, but treatment options remain limited. COVID-19 vaccination is expected to decrease the number of patients with COVID-19 worldwide. In Japan, two types of mRNA COVID-19 vaccine, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP) after BNT162b2 mRNA COVID-19 vaccination. Whether or not ITP is triggered by the vaccination or not is difficult to identify. Further investigation with a large number of cases is warranted to clarify the side effects of BNT162b2 mRNA COVID-19 vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19
Topics:
Vaccines
Limits:
Humans
Language:
Japanese
Journal:
Rinsho Ketsueki
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS